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Introduction
Activity-related dyspnea and exercise intolerance 
are important features of chronic obstructive pul-
monary disease (COPD) that negatively impact 
on ability to perform activities of daily living. As 
such, evaluating exercise tolerance is now consid-
ered to be an essential component of disease 
assessment.1 Of available exercise-testing proto-
cols, constant work-rate exercise tests, such as 
cycle and treadmill endurance tests and the 
endurance shuttle walk test (ESWT), are the 
most sensitive for detecting change in exercise 
capacity following intervention (pharmacologic 
and nonpharmacologic).2
Over the past several years, constant work-rate 
cycle ergometry (CWRCE) has been used exten-
sively in clinical trials evaluating the efficacy of 
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Abstract
Background: The TORRACTO® study evaluated the effects of tiotropium/olodaterol versus 
placebo on endurance time during constant work-rate cycling and constant speed shuttle 
walking in patients with chronic obstructive pulmonary disease (COPD) after 12 weeks of 
treatment.
Methods: The effects of once-daily tiotropium/olodaterol (2.5/5 and 5/5 μg) on endurance 
time during constant work-rate cycle ergometry (CWRCE) after 6 and 12 weeks of treatment 
were compared with placebo in patients with COPD in a randomized, double-blind, placebo-
controlled, parallel-group clinical trial. Endurance time during the endurance shuttle walk 
test (ESWT) after 6 and 12 weeks of treatment was also evaluated in a subset of patients.
Results: A total of 404 patients received treatment, with 165 participating in the ESWT 
substudy. A statistically significant improvement in endurance time during CWRCE was 
observed after 12 weeks (primary endpoint) with tiotropium/olodaterol 5/5 μg [14% (p = 
0.02)] but not with tiotropium/olodaterol 2.5/5 μg [9% (p = 0.14)] versus placebo. In the 
ESWT substudy, a trend to improvement in endurance time during ESWT after 12 weeks (key 
secondary endpoint) was observed with tiotropium/olodaterol 5/5 μg [21% (p = 0.055)] and 
tiotropium/olodaterol 2.5/5 μg [21% (p = 0.056)] versus placebo.
Conclusion: Tiotropium/olodaterol 5/5 μg improved endurance time during cycle ergometry 
versus placebo, with a strong tendency to also improve walking endurance time.
[ClinicalTrials.gov identifier: NCT01525615.]
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long-acting bronchodilators in patients with 
COPD,2,3 and is often included in clinical devel-
opment programs as a complementary assess-
ment of efficacy, alongside traditional assessments 
of lung function. There is, however, a debate 
regarding the most appropriate endurance exer-
cise testing protocol.2,4–7 In this regard, there has 
been recent interest in the ESWT,7–11 in some 
part due to a view that field walking tests are more 
reflective of activities performed by patients in 
everyday life.12
The TORRACTO® study was part of a clinical 
program evaluating the efficacy and safety of tio-
tropium/olodaterol in patients with COPD. 
TORRACTO® was designed to evaluate two 
doses of tiotropium/olodaterol (2.5/5 and 5/5 µg) 
compared with placebo on exercise endurance 
time (EET) during CWRCE in patients with 
COPD in a parallel-group design after 12 weeks 
of treatment. Secondary objectives were to evalu-
ate EET during the ESWT after 6 and 12 weeks 
of treatment with tiotropium/olodaterol in a sub-
set of patients.
Methods
TORRACTO® [ClinicalTrials.gov identifier: 
NCT01525615] was a multicenter, multinational, 
randomized, double-blind, placebo-controlled, 
parallel-group trial to evaluate the effects of once-
daily tiotropium/olodaterol (2.5/5 and 5/5 μg) 
compared with placebo on exercise tolerance after 
12 weeks of treatment in patients with COPD (5/5 
μg is the approved tiotropium/olodaterol dose). 
The primary evaluation of exercise tolerance was 
based on EET during CWRCE, while evaluation 
of EET during ESWT was conducted in a subset 
of patients (ESWT subgroup).
The study was conducted at 58 centers in 10 
countries. The ESWT substudy was conducted at 
a subset of 26 sites with experience in the ESWT; 
all patients at the selected sites were asked to par-
ticipate in the substudy.
Patients
Patients aged 40–75 years with a clinical diagno-
sis of COPD and stable airway obstruction were 
included if they had postbronchodilator forced 
expiratory volume in 1 s (FEV1)/forced vital 
capacity (FVC) <70% and postbronchodilator 
FEV1 <80% and ⩾30% predicted normal. 
Patients were current or exsmokers with a smok-
ing history of >10 pack-years. Exclusion criteria 
are detailed in the online supplement.
Study design
During screening, patients performed spirometry 
to determine study eligibility. Eligible patients 
were randomized to receive one of three treat-
ments: tiotropium/olodaterol 2.5/5 μg, tiotro-
pium/olodaterol 5/5 μg, or placebo, all delivered 
once daily via the Respimat® (Boehringer 
Ingelheim International GmbH, Ingelheim am 
Rhein, Germany) inhaler (Figure 1).
Throughout the 12-week treatment period, trial 
medication was self-administered by the patient 
once daily between 7 a.m. and 10 a.m.; on test 
days, administration of trial medication was per-
formed under research staff supervision. Patients 
continued with inhaled corticosteroids if taken at 
baseline. Open-label salbutamol (albuterol) was 
provided as rescue medication throughout the 
study.
The study was conducted in accordance with the 
Declaration of Helsinki and the International 
Conference on Harmonization Tripartite 
Guideline for Good Clinical Practice. Before the 
study started, the protocol was reviewed and 
approved by the Institutional Review Boards, and 
all patients provided written, informed consent.
Pulmonary function testing
Spirometry (FEV1, FVC) was performed using 
standard methodology.13 FEV1 and FVC measured 
Figure 1. Study design.
*Cycle ergometry testing; $endurance shuttle walk test; 
‡primary endpoint assessment.
R, randomization.
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immediately before the first dose of trial medication 
at the randomization visit was a priori defined as the 
pretreatment baseline. Spirometry was also per-
formed 1 h postdose at the randomization visit, and 
predose and 1 h postdose after 6 and 12 weeks of 
treatment.
Incremental cycle ergometry and constant 
work-rate cycle ergometry
The specific details of both incremental cycle 
ergometry and CWRCE have been described pre-
viously.14–16 During run-in, patients performed 
incremental cycle ergometry to symptom limita-
tion to determine peak work rate (Wpeak), the 
highest work rate maintained for ⩾30 s. Two 
CWRCE tests to symptom limitation at 75% 
Wpeak were performed during run-in: the first 
test familiarized the patient with the exercise pro-
tocol, while the second test ⩾4 days later was a 
priori defined as the pretreatment baseline. To 
avoid excessively long endurance times that may 
be limited by motivation rather than physiology/
symptoms, patients with an endurance time of 
>25 min in training or baseline CWRCE were not 
eligible for randomization. CWRCE at weeks 6 
and 12 was performed 2 h postdose. Additional 
information is provided in the online supplement.
Incremental and endurance shuttle walking 
(endurance shuttle walk test substudy)
Patients included in the ESWT substudy per-
formed an incremental shuttle walk test (ISWT) 
2–4 days after the initial screening visit.17 At 2–4 
days after the baseline and training CWRCE 
tests, training and baseline ESWTs were per-
formed at a walking speed corresponding to 85% 
of the peak oxygen consumption estimated from 
the ISWT.8 The ESWT was repeated at the same 
walking speed after 6 and 12 weeks of treatment, 
2 h postdose, again with a 2–4-day separation 
between the CWRCE and ESWT. Both the 
ISWT and ESWT were performed in an enclosed 
corridor on a flat 10-meter-long course. Patients 
who completed the highest level in the ISWT 
were not eligible for the substudy because a walk-
ing speed for the ESWT could not be established 
for these patients. Patients with an endurance 
time during the training or baseline ESWT of 
>15 min were excluded from the ESWT sub-
study due to the limited (20-min) duration of the 
audio used for pacing the ESWT. These patients 
did continue in the main part of the study 
(CWRCE). Further details are provided in the 
online supplement.
Breathing discomfort, leg discomfort, and 
inspiratory capacity
During CWRCE and ESWT, patients rated 
intensity of breathing discomfort and leg discom-
fort using the modified Borg scale18 at rest, during 
each 2-min interval during exercise, and at the 
end of exercise. During CWRCE (but not ESWT) 
patients also performed an inspiratory capacity 
(IC) maneuver after each rating of breathing and 
leg discomfort. Immediately after completing 
exercise, patients were asked to identify the pri-
mary reason for stopping exercise using a previ-
ously described questionnaire.19
Safety assessments
At each visit, adverse events (AEs) reported by 
the patient were recorded irrespective of causal-
ity. Pulse rate and systolic and diastolic blood 
pressure were measured at each clinic visit imme-
diately prior to spirometry. Clinical laboratory 
testing (hematology, blood chemistry, and uri-
nalysis) and a resting 12-lead electrocardiogram 
were performed at screening and at week 12.
Efficacy endpoints
The primary endpoint was EET during CWRCE 
after 12 weeks of treatment. Owing to the skew-
ness of the EET data during CWRCE,20 the pri-
mary analysis was prespecified to be based on the 
logarithm to the base 10 of EET during CWRCE. 
The key secondary endpoint was EET during 
ESWT after 12 weeks of treatment (ESWT sub-
group), also based on log10-transformed data.
Other exercise-related efficacy endpoints included 
pre-exercise, isotime, and end-exercise IC during 
CWRCE, and intensity of breathing and leg dis-
comfort during CWRCE and ESWT.
Isotime for each patient was defined as the mini-
mum EET among the pretreatment baseline, 
week 6, and week 12 CWRCE tests. Isovalue was 
defined as the value of a specific parameter at iso-
time. This isovalue could be an observed value 
(e.g. when it occurred at the end of exercise) or it 
could be determined by interpolation between the 
values at the two time points immediately above 
and below the isotime.
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FEV1 and FVC (trough and 1 h postdose) were 
also measured to confirm bronchodilator efficacy.
Statistical analysis
Mean log10 EETs from CWRCE and ESWT were 
analyzed using a restricted maximum likelihood-
based mixed-effects model repeated measure 
(MMRM) approach. Analyses included the fixed, 
categorical effect of treatment, test day, and treat-
ment-by-test-day interaction, as well as the continu-
ous, fixed covariates of baseline and baseline- 
by-test-day interaction. The baseline covariate term 
also used the logarithm to the base 10. The primary 
analysis was performed on the full analysis set (i.e. all 
randomized patients who received at least one dose 
of treatment, and who had both baseline and at least 
one postbaseline measurement at or before 12 weeks 
for the primary efficacy endpoints).
Based on a previous trial,21 an appropriate esti-
mate of the standard deviation for log10 EET from 
CWRCE was 0.206; with this standard deviation, 
a sample size of 130 patients per group provided 
90% power to detect a 21% improvement in EET 
during CWRCE.
Analyses for EET during CWRCE at 12 weeks 
(primary endpoint), EET during ESWT at 12 
weeks (key secondary endpoint), and pre-exercise 
IC during CWRCE at 12 weeks (secondary end-
point) were included in a step-down hierarchical 
testing strategy. Testing strategy details are pro-
vided in the online supplement (Figure S1).
The same MMRM approach was adopted for all 
other continuous secondary endpoints. Adjusted 
mean values as well as treatment contrasts were 
presented, together with 95% confidence inter-
vals. Secondary endpoints (i.e. other than EET 
during ESWT and pre-exercise IC at 12 weeks) 
were not included in the step-down hypothesis-
testing hierarchy and are considered descriptive 
(nominal p values).
All treated patients were included in the safety 
analyses, which were descriptive in nature.
Results
Patient disposition and baseline characteristics
A total of 404 patients were randomized and 
received treatment (Figure 2), with 385 included 
in the full analysis set.
Baseline patient characteristics for the treated set are 
shown in Table 1. Overall, 73% were Global 
Initiative for Chronic Obstructive Lung Disease 
stage 2, with mean predicted normal FEV1 of 58.6%.
Baseline exercise-specific patient characteristics 
for the treated set are shown in Table 2. Baseline 
characteristics were generally well balanced across 
treatment groups.
A total of 165 patients were included in the 
ESWT subgroup. Baseline patient characteristics 
and exercise-specific characteristics for the ESWT 
subgroup are shown in Tables 1 and 3, respec-
tively. Baseline characteristics were generally well 
balanced across treatment groups.
Two patients had an EET during CWRCE at 
baseline of >25 min (i.e. screen failure); 11 
patients had an EET during ESWT at baseline of 
>15 min (i.e. not included in the ESWT sub-
study, but continued in the main study).
Constant work-rate cycle ergometry (full 
analysis set)
Common baseline geometric mean EET [stand-
ard error (SE)] during CWRCE was 443.0 (12.4) 
s. Geometric mean (SE) EET during CWRCE at 
week 12 (primary endpoint) was 463.6 (18.8) s 
for placebo, 503.6 (19.6) s for tiotropium/ 
olodaterol 2.5/5 µg, and 527.5 (20.2) s for tiotro-
pium/olodaterol 5/5 µg, with a statistically signifi-
cant increase of 13.8% compared with placebo 
for tiotropium/olodaterol 5/5 µg (p = 0.02) and 
an increase of 8.6% compared with placebo for 
tiotropium/olodaterol 2.5/5 µg (p = 0.14) (Figure 
3). Since the comparison for tiotropium/olo-
daterol 2.5/5 µg compared with placebo did not 
reach statistical significance, subsequent hypoth-
esis tests within the step-down hypothesis-testing 
strategy are considered descriptive rather than 
confirmatory (nominal p values).
Geometric mean (SE) EET at week 6 was 427.7 
(17.1) s for placebo, 522.3 (20.2) s for tiotropium/
olodaterol 2.5/5 µg, and 525.6 (20.0) s for tiotro-
pium/olodaterol 5/5 µg, with a 22.9% increase 
compared with placebo for tiotropium/olodaterol 
5/5 µg (nominal p = 0.0002) and a 22.1% increase 
compared with placebo for tiotropium/olodaterol 
2.5/5 µg (nominal p = 0.0004) (Figure 3).
The common mean IC values at baseline 
were: pre-exercise, 2397 ml; isotime, 2131 ml; and 
F Maltais, D O’Donnell et al.
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end-exercise, 2111 ml. Mean IC increased at pre-
exercise, isotime, and end-exercise for both tiotro-
pium/olodaterol doses compared with placebo at 
weeks 6 and 12 (Figure 4a) (nominal p < 0.05 at 
all time points for tiotropium/olodaterol 2.5/5 and 
5/5 µg).
The rate of increase in intensity of breathing dis-
comfort (Borg scale) during exercise [(end of 
exercise Borg score minus pre-exercise Borg 
score)/EET] was lower for both tiotropium/olo-
daterol doses compared with placebo at weeks 6 
and 12 (Figure 4b) (nominal p = 0.0218 for tio-
tropium/olodaterol 2.5/5 µg and p = 0.0598 for 
tiotropium/olodaterol 5/5 µg at week 12).
For both tiotropium/olodaterol 2.5/5 and 5/5 µg, 
increases in FEV1 and FVC were observed 1 h 
after the first dose, and predose and 1 h postdose 
after 6 and 12 weeks.
Endurance shuttle walking (ESWT substudy)
Common baseline geometric mean EET (SE) dur-
ing ESWT was 311.2 (13.7) s. Geometric mean 
(SE) EET during ESWT at week 12 (key secondary 
endpoint) was 311.4 (22.5) s for placebo, 377.2 
(25.9) s for tiotropium/olodaterol 2.5/5 µg, and 
376.4 (25.0) s for tiotropium/olodaterol 5/5 µg, with 
an increase of 20.9% compared with placebo for 
tiotropium/olodaterol 5/5 µg (nominal p = 0.055) 
and an increase of 21.1% compared with placebo 
for tiotropium/olodaterol 2.5/5 µg (nominal p = 
0.056) (Figure 5). One patient on placebo, four 
patients on tiotropium/olodaterol 2.5/5 µg, and two 
patients on tiotropium/olodaterol 5/5 µg reached 
test termination (i.e. 20-min duration).
Geometric mean (SE) ESWT EET at week 6 was 
312.0 (22.5) s for placebo, 377.9 (25.8) s for tiotro-
pium/olodaterol 2.5/5 µg, and 376.2 (24.9) s for 
tiotropium/olodaterol 5/5 µg, with an increase of 
20.6% compared with placebo for tiotropium/olo-
daterol 5/5 µg (nominal p = 0.058) and an increase 
of 21.1% compared with placebo for tiotropium/
olodaterol 2.5/5 µg (nominal p = 0.055) (Figure 5). 
No patients on placebo, three patients on tiotro-
pium/olodaterol 2.5/5 µg, and two patients on tio-
tropium 5/5 µg reached test termination (i.e. 
20-min duration).
Figure 2. CONSORT diagram.
CONSORT, Consolidated Standards of Reporting Trials; O, olodaterol; T, tiotropium.
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Table 1. Baseline patient characteristics (treated set and endurance shuttle walk test subgroup).
Treated set (n = 404) ESWT subgroup (n = 165)
 Placebo  
(n = 132)
T/O 2.5/5 µg 
(n = 133)
T/O 5/5 µg  
(n = 139)
Placebo  
(n = 50)
T/O 2.5/5 µg 
(n = 56)
T/O 5/5 µg  
(n = 59)
Male, n (%) 87 (65.9) 87 (65.4) 95 (68.3) 31 (62.0) 38 (67.9) 45 (76.3)
Mean (SD) age, years 60.8 (7.6) 61.9 (7.3) 63.1 (7.5) 61.3 (6.4) 64.2 (7.7) 65.4 (7.0)
Mean (SD) prebronchodilator
 FEV1, l 1.501 (0.507) 1.465 (0.526) 1.460 (0.476) 1.449 (0.430) 1.360 (0.417) 1.377 (0.425)
Mean (SD) postbronchodilator
 FEV1, l 1.695 (0.522) 1.616 (0.474) 1.659 (0.504) 1.646 (0.413) 1.566 (0.419) 1.588 (0.451)
  % predicted normal FEV1 59.7 (12.9) 57.9 (12.9) 58.2 (12.8) 60.2 (11.5) 57.7 (12.7) 57.4 (13.9)
  FEV1 change from 
prebronchodilator, l
0.194 (0.155) 0.152 (0.224) 0.199 (0.192) 0.197 (0.154) 0.206 (0.164) 0.211 (0.109)
 FEV1/FVC, % 52.5 (10.0) 51.4 (10.5) 51.9 (10.7) 52.8 (98) 51.3 (10.0) 51.3 (11.5)
GOLD*, n (%)
 2 99 (75.0) 92 (69.2) 104 (74.8) 39 (78.0) 40 (71.4) 44 (74.6)
 3 32 (24.2) 41 (30.8) 31 (22.3) 11 (22.0) 16 (28.6) 12 (20.3)
Mean (SD) body mass index, 
kg/m2
26.9 (5.1) 26.8 (5.2) 27.4 (5.0) 28.2 (5.2) 27.4 (4.6) 27.7 (5.1)
Current smoker, n (%) 58 (43.9) 58 (43.6) 51 (36.7) 23 (46.0) 25 (44.6) 16 (27.1)
Exsmoker, n (%) 74 (56.1) 75 (56.4) 88 (63.3) 27 (54.0) 31 (55.4) 43 (72.9)
Mean (SD) smoking history, 
pack-years
44.0 (22.2) 48.6 (28.1) 46.0 (22.1) 45.3 (22.8) 53.3 (31.4) 45.6 (23.6)
Baseline pulmonary medications, n (%)
 SAMA** 12 (9.1) 9 (6.8) 13 (9.4)  
 LAMA‡ (tiotropium) 58 (43.9) 70 (52.6) 68 (48.9)  
 SABA§,$ (inhaled) 78 (59.1) 76 (57.1) 69 (49.6)  
 LABA‡ (inhaled) 66 (50.0) 76 (57.1) 82 (59.0)  
 Inhaled steroids 68 (51.5) 68 (51.1) 76 (54.7)  
 Xanthines§ 11 (8.3) 13 (9.8) 13 (9.4)  
* GOLD 1 and 4 patients were excluded from the study.
$ All patients were provided with SABA as a rescue medication during this study.
‡ Patients switched to study medication during treatment period.
§ Permitted during treatment period.
** Not permitted during treatment period.
ESWT, endurance shuttle walk test; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive 
Lung Disease; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; O, olodaterol; SABA, short-acting β-agonist; SAMA, short-
acting muscarinic antagonist; SD, standard deviation; T, tiotropium.
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Decreases in the rate of increase in intensity of 
breathing discomfort (Borg scale) were observed 
with both tiotropium/olodaterol doses compared 
with placebo at weeks 6 and 12 (online supple-
ment Figure S2).
Arithmetic versus log10-transformed treatment 
effects
To facilitate the interpretation and comparisons 
across studies, the more ‘traditional’ approach 
based on arithmetic EET data is provided for 
Table 2. Baseline incremental and constant work-rate cycle ergometry characteristics (treated set).
Treated set (n = 404)
 Placebo (n = 132) T/O 2.5/5 µg (n = 133) T/O 5/5 µg (n = 139)
Peak work rate (SD) during incremental 
cycle ergometry, W
87.8 (30.7) 86.2 (26.7) 87.0 (27.4)
Mean (SD) baseline EET during CWRCE, s 502.7 (258.6) 490.7 (272.4) 527.5 (279.2)
Mean (SD) baseline IC, l
 At rest 2.40 (0.76) 2.33 (0.66) 2.44 (0.68)
 End-exercise 2.15 (0.70) 2.03 (0.62) 2.13 (0.64)
  Mean (SD) breathing discomfort at end-
exercise, Borg units
6.5 (2.4) 6.3 (2.8) 6.6 (2.6)
Mean (SD) leg discomfort at end-exercise, 
Borg units
6.5 (2.7) 6.3 (2.9) 6.4 (2.9)
Locus of symptom limitation, n (%)
 Breathing discomfort 43 (32.6) 49 (36.8) 41 (29.5)
 Breathing/leg discomfort 56 (42.4) 53 (39.8) 59 (42.4)
 Leg discomfort 32 (24.2) 28 (21.1) 37 (26.6)
CWRCE, constant work-rate cycle ergometry; EET, exercise endurance time; IC, inspiratory capacity; O, olodaterol; SD, standard deviation; T, 
tiotropium.
Table 3. Baseline endurance shuttle walk test characteristics (endurance shuttle walk test subgroup, n = 165).
Placebo (n = 50) T/O 2.5/5 µg (n = 56) T/O 5/5 µg (n = 59)
Mean (SD) baseline EET, s 346.3 (186.5) 366.7 (206.0) 373.7 (217.1)
Median (minimum, maximum) baseline EET, s 320.0 (91, 792) 315.5 (85, 830) 317.0 (88, 872)
Mean (SD) breathing discomfort at end-
exercise, Borg units
6.4 (2.9) 6.5 (2.8) 6.9 (2.4)
Mean (SD) leg discomfort at end-exercise, 
Borg units
5.6 (3.2) 5.0 (3.3) 5.3 (3.5)
Locus of symptom limitation, n (%)
 Breathing discomfort 27 (54.0) 33 (58.9) 35 (59.3)
 Breathing/leg discomfort 13 (26.0) 9 (16.1) 14 (23.7)
 Leg discomfort 10 (20.0) 14 (25.0) 10 (16.9)
EET, exercise endurance time; O, olodaterol; SD, standard deviation; T, tiotropium.
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comparison to the log10-transformed data [online 
supplement Tables S2 and S3 (CWRCE) and 
Tables S4 and S5 (ESWT)]. Using the arithmetic 
data, there were 25.0 and 14.4% increases in EET 
during CWRCE with tiotropium/olodaterol 5/5 µg 
over placebo at 6 and 12 weeks, respectively.
Safety (treated set)
Incidences of AEs, serious AEs, and AEs leading to 
discontinuation with tiotropium/olodaterol 2.5/5 
and 5/5 µg were similar to placebo (online supple-
ment Table S6). Most AEs were mild to moderate 
in severity and not considered related to study 
medication by the investigator. The most common 
AE was COPD exacerbation, which occurred in 
12.1%, 11.3%, and 7.2% of patients receiving pla-
cebo, tiotropium/olodaterol 2.5/5 µg, and tiotro-
pium/olodaterol 5/5 µg, respectively. Two deaths 
occurred during the study, both in patients receiv-
ing tiotropium/olodaterol 2.5/5 µg: one patient died 
from lung cancer and the other from cardio-respir-
atory arrest (this event did not occur during the 
exercise testing). Neither was considered related to 
study drug by the investigator.
Discussion
In this study, tiotropium/olodaterol 5/5 µg 
increased EET during CWRCE by 13.8% com-
pared with placebo after 12 weeks in patients with 
moderate to severe COPD (primary endpoint). In 
the ESWT substudy, a 20.9% increase in EET 
for tiotropium/olodaterol 5/5 µg compared with 
placebo after 12 weeks did not reach statistical 
significance (p = 0.055).
The effects of tiotropium/olodaterol on EET dur-
ing CWRCE in moderate to very severe COPD 
have also been investigated in two replicate, dou-
ble-blind, crossover studies of 6-week duration 
(MORACTO®).22 Similar to the present study, 
the MORACTO® studies evaluated two doses of 
tiotropium/olodaterol (2.5/5 and 5/5 µg), and 
included placebo, tiotropium 5 µg alone, and olo-
daterol 5 µg alone as comparator arms to evaluate 
the efficacy of tiotropium/olodaterol compared 
with placebo and its added benefit over the indi-
vidual monotherapies. The TORRACTO® study 
was designed to complement the MORACTO® 
studies by determining whether the effects of tio-
tropium/olodaterol compared with placebo on 
Figure 3. Geometric mean exercise endurance time during constant work-rate cycle ergometry after 6 and 12 
weeks.
*Geometric mean results are reported as the primary analysis based on log10-transformed data; week 6 data are not 
included in hierarchical testing sequence and should be considered descriptive only.
Common geometric mean baseline EET: 443.0 s.
Placebo, n = 121; T/O 2.5/5 μg, n = 129; T/O 5/5 μg, n = 135.
EET, exercise endurance time; O, olodaterol; SE, standard error; T, tiotropium.
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EET during CWRCE were maintained up to 12 
weeks to document the duration of effect.
EET during CWRCE for tiotropium/olodaterol 
5/5 µg was similar at 6 weeks (geometric mean: 
525.6 s) and 12 weeks (geometric mean: 527.5 
s), representing 18.6 and 19.1% improve-
ments, respectively, compared with a baseline 
geometric mean EET of 443.0 s. Statistically 
significant improvements in EET for tiotro-
pium/olodaterol 5/5 µg compared with placebo 
were observed after both 6 and 12 weeks, with 
differences in response magnitude (22.9% 
improvement after 6 weeks, 13.8% improve-
ment after 12 weeks) explained by variability in 
EET in the placebo arm (geometric means of 
427.7 and 463.6 s after 6 and 12 weeks, 
respectively).
Figure 4. Mean inspiratory capacity (a) and slope of intensity (b) of breathing discomfort after 12 weeks.
Mean baseline IC: pre-exercise, 2397 ml; isotime, 2131 ml; end-exercise, 2111 ml.
T/O 2.5/5 μg versus placebo, p = 0.0218; T/O 5/5 μg versus placebo, p = 0.0598.
IC, inspiratory capacity; O, olodaterol; SE, standard error; T, tiotropium.
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Tiotropium/olodaterol 2.5/5 µg did not achieve 
statistical significance for the primary endpoint 
(EET during CWRCE after 12 weeks). However, 
several lines of evidence point to an effect of the 
lower dose on exercise endurance: (i) tiotropium/
olodaterol 2.5/5 µg significantly improved EET 
during CWRCE compared with placebo in both 
MORACTO® studies [26.5% (p < 0.0001) and 
12.1% (p = 0.0003)]; (ii) there was a nominally 
significant improvement in EET during CWRCE 
after 6 weeks (22.1%, nominal p = 0.0004) in the 
present study; (iii) in post hoc analysis, change 
from baseline in EET during CWRCE after 6 and 
12 weeks was nominally significant.
Endurance time during ESWT has been used as 
an outcome measure in pulmonary rehabilitation 
studies for many years.23 Recently, there has been 
increased attention on ESWT as a methodology to 
evaluate bronchodilator efficacy. Early single-
center studies provided promising results, showing 
that endurance time during ESWT offered a sensi-
tive test to assess bronchodilation in patients with 
COPD.7,9–11 However, multicenter, multinational 
studies have value in supporting generalizability, as 
has been done for CWRCE.21,24–32 At the time of 
study initiation in March 2012, there were no pub-
lished studies using a multicenter trial with ESWT 
to evaluate the effects of pharmacotherapy in 
COPD. The first multicenter study was conducted 
in 2010–2011, with results published in 2013.33 
Two replicate, multicenter studies were conducted 
in 2011–2012, with results published in 2014.34
The present study adds to the knowledge about 
the use of ESWT to assess the effects of bron-
chodilation on exercise capacity in patients with 
COPD in a multicenter setting. Based on the 
methodologic concerns regarding the transition 
from a single-center to a multicenter setting, a 
high degree of attention was placed on trial over-
sight with respect to the training and monitoring 
of the ESWT. Details of these quality control 
efforts are described in the online supplement as 
reference for other researchers interested in con-
ducting multicenter studies using ESWT. The 
ESWT performed well in this trial; the lack of a 
learning effect in the placebo arm (i.e. similar 
EET in placebo arm at baseline and after 6 and 
12 weeks) suggests that study participants were 
able to produce reproducible exercise tests. 
Future efforts to determine the minimal quality 
control criteria in multicenter ESWT studies are 
warranted.
Although statistical significance was just missed (p 
= 0.055), the observed 20% improvement in EET 
in ESWT at 6 and 12 weeks with both doses of 
tiotropium/olodaterol is beyond the proposed min-
imally important difference for this parameter.35 
With the recognition that the ESWT has a fixed 
test termination of 20 min,8 study eligibility criteria 
included a baseline EET of <15 min to allow for 
sufficient post-treatment endurance times within 
the 20-min test. This was the case for the majority 
of patients, but one patient in the placebo group, 
four patients in the tiotropium/olodaterol 2.5/5 µg 
Figure 5. Geometric mean endurance shuttle walk test endurance time after 6 and 12 weeks in the endurance 
shuttle walk test subgroup.
*Geometric mean results reported as primary analysis based on log10-transformed data; week 6 data are not included in 
hierarchical testing sequence and should be considered descriptive only.
Common geometric mean baseline ESWT endurance time: 311.2 s.
Placebo, n = 50; T/O 2.5/5 μg, n = 56; T/O 5/5 μg, n = 59.
ESWT, endurance shuttle walk test; O, olodaterol; SE, standard error; T, tiotropium.
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group, and two patients in the tiotropium/olo-
daterol 5/5 µg group reached the 20-min test ter-
mination time point during ESWT after 12 weeks 
(i.e. did not reach symptom limitation). This may 
have contributed to reducing the statistical power 
of the study. A more recent study (PHYSACTO®), 
with a greater sample size than the present study 
(65–72 patients per treatment arm), has shown 
significant improvements in EET during ESWT 
after 8 weeks of treatment with tiotropium/olo-
daterol compared with placebo in patients who 
participated in a self-management behavior-change 
program (29% increase, p < 0.01).23
An important methodologic consideration in rela-
tion to the current trial is that statistical analyses 
were performed on log10-transformed endurance 
time data. Although these analyses are justified in 
that endurance time during constant work-rate 
exercise is asymmetrically distributed around the 
mean, with a significant skew towards long 
EETs,20,36 this approach complicates compari-
sons with previous trials.
For the purpose of facilitating comparisons across 
studies, we also report arithmetic mean treatment 
effects of tiotropium/olodaterol versus placebo, 
which ranged from 118 s to 124 s, or ~25% 
increase over placebo for CWRCE at week 6. 
Despite expected differences in adjusted mean 
values between untransformed and log10-trans-
formed approaches, relative (%) increases in EET 
for active treatment arms versus placebo and the 
respective statistical significances were very simi-
lar for the two statistical approaches, supporting 
the robustness of the findings.
The improvements in EET versus placebo are 
consistent with what is expected from single and 
dual long-acting bronchodilators.21,25,28,32,36,37 
Also, increases in EET in CWRCE with active 
treatments in the present study were beyond the 
estimated range for a clinically meaningful differ-
ence, compared with placebo, of 46–105 s for 
endurance time, as proposed by the European 
Respiratory Society task force on outcomes in 
COPD.38 Despite not reaching formal statistical 
significance, the increase in EET during ESWT, 
averaging 81–88 s or 21% at week 6, compared 
advantageously with previous publications (121 s, 
31% at 3 weeks;39 47 s, 15% at 12 weeks34). The 
increase in EET during ESWT with tiotropium/
olodaterol was also beyond the proposed clini-
cally meaningful difference.35
The primary evidence of clinical efficacy to sup-
port the health authority approval of tiotropium/
olodaterol 5/5 µg was based on the observed effects 
on lung function (FEV1) and health-related qual-
ity of life (St. George’s Respiratory Questionnaire) 
in the 52-week TONADO® studies. However, 
exercise capacity has been recommended as an 
important additional clinical outcome in COPD 
pharmacologic trials.40 The results from the pre-
sent TORRACTO® study, as well as from the pre-
viously reported MORACTO® studies, extend the 
clinical evaluation of tiotropium/olodaterol 5/5 µg, 
and provide a more complete characterization of 
therapeutic benefit at the impairment-disability 
interface. The results show that the primary effects 
of tiotropium/olodaterol 5/5 µg on lung function 
lead to clinically meaningful downstream improve-
ments in the capacity to perform different types of 
exercise (cycling, walking), which is arguably a 
more meaningful outcome to patients with COPD, 
who struggle to perform daily activities due to 
exertional breathlessness.
Conclusion
Tiotropium/olodaterol 5/5 µg improved endur-
ance time during cycle ergometry versus placebo, 
with a strong tendency to also improve walking 
endurance.
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